Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Recruiting · Phase 3 · NCT07007962
Conditions: Immune Thrombocytopenia
At a glance
- Research payments reported, 2025
- $11,250
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Sanofi
- Tested
- rilzabrutinib (drug)
- Dates
- Started 2025-10-24; completion 2028-12-30
- Results posted
- Not yet
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $11,250 in research payments for this study in 2025 (1 payments).
Products named: Wayrilz
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Community Cancer Trials of Utah, Llc $11,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.